Comments
Lupin on Monday said it has received an approval from the US Food and Drug Administration to market its Triamcinolone Acetonide ointment, used to treat skin conditions, in the US. The drug is a generic version of Mylan Pharmaceuticals Inc’s Triamcinolone Acetonide Ointment, Lupin said. As per the IQVIA MAT June 2018 sales data, the ointment had annual sales of around $25.7 million in the US. Lupin shares ended 0.51 per cent up at ₹882.10 on the BSE on Monday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.